Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab for Orbital and Periocular Cutaneous Squamous Cell Carcinoma (cSCC)

NCT06580054 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT06580054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06580054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab for Orbital and Periocular Cutaneous Squamous Cell Carcinoma (cSCC)
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 5, 2025
Completion date
December 31, 2026
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cutaneous squamous cell carcinoma of the head and neck, recurrent cutaneous squamous cell carcinoma of the head and neck, stage iii cutaneous squamous cell carcinoma of the head and neck ajcc v8